Conference
Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut).
Authors
Ferrarotto R; Metcalf R; Rodriguez CP; Muzaffar J; Even C; Perez A; Herpen CML-V; Oliva M; Xia B; Bowles DW
Volume
40
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
June 1, 2022
Name of conference
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
ELECTR NETWORK
Conference start date
June 3, 2022
Conference end date
June 7, 2022
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
16
ISSN
0732-183X